MDPI and ACS Style
Demirsoy, S.; Tran, H.; Liu, J.; Li, Y.; Yang, S.; Aregawi, D.; Glantz, M.J.; Jacob, N.K.; Walter, V.; Schell, T.D.;
et al. Targeting Tyro3, Axl, and MerTK Receptor Tyrosine Kinases Significantly Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibition. Cancers 2024, 16, 2253.
https://doi.org/10.3390/cancers16122253
AMA Style
Demirsoy S, Tran H, Liu J, Li Y, Yang S, Aregawi D, Glantz MJ, Jacob NK, Walter V, Schell TD,
et al. Targeting Tyro3, Axl, and MerTK Receptor Tyrosine Kinases Significantly Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibition. Cancers. 2024; 16(12):2253.
https://doi.org/10.3390/cancers16122253
Chicago/Turabian Style
Demirsoy, Seyma, Ha Tran, Joseph Liu, Yunzhan Li, Shengyu Yang, Dawit Aregawi, Michael J. Glantz, Naduparambil K. Jacob, Vonn Walter, Todd D. Schell,
and et al. 2024. "Targeting Tyro3, Axl, and MerTK Receptor Tyrosine Kinases Significantly Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibition" Cancers 16, no. 12: 2253.
https://doi.org/10.3390/cancers16122253